Every 10-Q that Prestige Consumer Healthcare Inc. (PBH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PBH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBH filings page.
Prestige Consumer Healthcare Inc. reported total revenues of 265,710 (stated in thousands of dollars) for the three months ended June 30, 2026, up 6.5% from 249,530. Growth came mainly from North American OTC Healthcare, especially Wellness, Sleep & Other and Gastrointestinal categories, but gross profit fell 3.0% to 136,188 (in thousands). Net income declined to 29,177 (in thousands), with basic and diluted EPS of $0.61 versus $0.96 and $0.95 a year earlier, driven by lower margins and higher expenses.
On June 12, 2026, the company completed the $1,045.0 million cash acquisition of the OTC Wellness Business, including Breathe Right and other brands, funded by a new $1,045,000 (in thousands) Term Loan Credit Agreement maturing in 2033. This added 31,126 (in thousands) of inventories, 948,370 (in thousands) of intangible assets and 65,504 (in thousands) of goodwill, lifting total goodwill to 650,795 (in thousands) and intangible assets, net, to 3,243,358 (in thousands). Total long-term debt including current portion rose to 2,045,000 (in thousands), while cash and cash equivalents increased to 89,127 (in thousands), supported by 70,788 (in thousands) of operating cash flow.
Subsequent to quarter-end, Prestige closed the approximately $150.0 million LaCorium Health acquisition, funded partly by an additional $95.0 million term loan draw, and issued $400.0 million of 6.25% senior notes due 2034 to redeem all $400.0 million of its 5.125% 2019 Senior Notes. The company highlights ongoing supply-chain pressures, particularly for sterile eye care products, and significant customer and supplier concentration, with Walmart and Amazon representing 19% and 16% of gross revenues, respectively, and one key supplier accounting for 22%.
Prestige Consumer Healthcare Inc. reported softer results for the quarter ended December 31, 2025. Total revenues slipped 2.4% to $283.4 million, with declines in both North American and International OTC segments, mainly from weaker Eye & Ear Care sales. Quarterly net income fell to $46.7 million, or $0.97 per diluted share, down from $61.0 million and $1.22 a year earlier, reflecting lower sales, higher general and administrative costs and a $10.3 million supplier loan write-off.
For the first nine months of fiscal 2026, revenues declined 4.1% to $807.1 million and net income decreased to $136.4 million from $164.5 million, while gross margin ticked higher on favorable mix. The company completed two acquisitions, including Pillar5 Pharma for a preliminary $111.9 million, added goodwill and intangibles, generated strong operating cash flow of $214.8 million, and used $155.6 million to repurchase shares, ending with $62.4 million in cash and $1.04 billion of long-term debt.
Prestige Consumer Healthcare (PBH) reported Q2 results. Total revenues were $274.1 million for the three months ended September 30, 2025, down 3.4% year over year. Net income was $42.2 million and diluted EPS was $0.86. Gross margin was 55.3%, slightly lower than 55.5% a year ago as International margins softened. Operating income was $79.7 million, while the effective tax rate rose to 38.9% primarily due to a new state tax presence.
For the six months, revenues were $523.6 million (down 5.0%) and operating cash flow reached $136.5 million. The company repurchased $109.8 million of stock at an average price of $70.34, ending with $119.1 million in cash. Long‑term debt remained $1.0 billion, with $190.0 million of unused capacity on the 2012 ABL Revolver. North American sales declined on Eye & Ear Care shortages, while Gastrointestinal grew; International revenue was roughly flat with mixed category performance.